The treatment of hyperuricemia
Micaela Gliozzi1, Natalia Malara1, Saverio Muscoli1
1Institute of Research for Food Safety & Health (IRC-FSH), University "Magna Graecia" of Catanzaro, Italy.
Hyperuricemia, a cause of gout, involves vascular inflammation. Novel treatments targeting xanthine oxidoreductase (XO) and URAT1 may reduce uric acid levels and oxidative stress, benefiting conditions like diabetes and heart failure.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Nephrology
Background:
- Hyperuricemia is the primary cause of gout and contributes to vascular inflammation.
- Traditional treatments focus on acute gout attacks, neglecting chronic urate deposition.
- Chronic hyperuricemia leads to endothelial dysfunction, impacting diabetes, hypertension, and heart failure.
Purpose of the Study:
- To review recent evidence on xanthine oxidoreductase (XO) inhibitors and uricosuric compounds.
- To highlight novel XO inhibitors for reducing uric acid overproduction.
- To explore the link between lowering uric acid and mitigating oxidative stress and endothelial dysfunction.
Main Methods:
- Review of recent scientific literature on XO inhibitors and uricosuric agents.
- Analysis of studies focusing on novel XO inhibitors' efficacy.
- Correlation of uric acid lowering with oxidative stress and endothelial function markers.
Main Results:
- XO inhibitors and uricosuric compounds effectively lower uric acid in blood and tissues.
- Novel XO inhibitors show promise in reducing uric acid overproduction.
- Lowering uric acid levels via XO inhibition attenuates oxidative stress and improves endothelial function.
Conclusions:
- Targeting XO and URAT1 offers a promising strategy for managing chronic hyperuricemia beyond acute gout.
- Novel XO inhibitors represent a significant advancement in controlling uric acid levels.
- Reducing XO-generated radicals may prevent tissue damage and address comorbidities like cardiovascular diseases.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Antihypertensive Drugs: Action of Diuretics
Pharmaceutical Poisoning: Treatment Strategies
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)

